US 12,064,450 B2
Tumoricidal and antimicrobial compositions and methods
Hans G. Klingemann, Boston, MA (US); and Barry J. Simon, Culver City, CA (US)
Assigned to ImmunityBio, Inc., San Diego, CA (US)
Filed by ImmunityBio, Inc., San Diego, CA (US)
Filed on Feb. 22, 2022, as Appl. No. 17/677,727.
Application 16/598,418 is a division of application No. 15/032,518, granted, now 10,258,649, issued on Apr. 16, 2019, previously published as PCT/US2014/062695, filed on Oct. 28, 2014.
Application 17/677,727 is a continuation of application No. 17/539,155, filed on Nov. 30, 2021.
Application 17/539,155 is a continuation of application No. 16/598,418, filed on Oct. 10, 2019, granted, now 11,304,977.
Application 17/539,155 is a continuation of application No. 16/289,494, filed on Feb. 28, 2019, granted, now 10,517,895.
Claims priority of provisional application 61/899,066, filed on Nov. 1, 2013.
Prior Publication US 2022/0175838 A1, Jun. 9, 2022
Int. Cl. A61K 35/17 (2015.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 9/50 (2006.01); A61K 38/20 (2006.01); C12N 5/0783 (2010.01); A61K 35/12 (2015.01)
CPC A61K 35/17 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/5068 (2013.01); A61K 38/2013 (2013.01); C12N 5/0646 (2013.01); A61K 2035/124 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A production intermediate for a cell-based product, comprising:
a plurality of NK-92 cells in a culture medium comprising (i) IL-15, and (ii) L-asparagine, L-glutamine, and L-serine;
wherein the NK-92 cells are a subpopulation of wild type NK-92 cells or modified NK-92 cells, wherein the subpopulation of the modified NK-92 cells have been modified to express (i) an Fc receptor selected from the group consisting of an Fcγ receptor, CD16 (FcγRIII-A), FCγRI (CD64), FCγRII (CD32), FCγRIII, FcRn, Fcα, and Fcε; or (ii) CD16, CD16-γ, or CD16-C; or (iii) IL-2, an IL-2 receptor, IL-15, an IL-15 receptor, IL-18, an IL-18 receptor, IL-21, and/or an IL-21 receptor;
wherein the subpopulation of wild type NK-92 cells or modified NK-92 cells produces cytotoxic exosomes when grown in the culture medium; and
wherein the culture medium comprises exosomes and/or microvesicles that were produced by the subpopulation of wild type NK-92 cells or modified NK-92 cells in the culture medium.